FindTrial
Sign In

A Study on CDK4/6 Inhibitor Resistance in metastatic hormone receptor-positive breast cancer patients

Immunological resistance mechanism of CDK4/6 inhibitor in metastatic hormone receptor-positive breast cancer patients

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0009856
Enrollment
65
Registered
2024-10-17
Start date
2024-10-01
Completion date
Unknown
Last updated
2024-11-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

National Cancer Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Aged 20 years or older 2. Voluntarily consented to participate in the study 3. Metastatic hormone receptor-positive breast cancer 4. Patients who are receiving or are scheduled to receive CDK4/6 inhibitor treatment

Exclusion criteria

Exclusion criteria: In cases where there is insufficient tissue available for immunocyte analysis

Design outcomes

Primary

MeasureTime frame
blood cytokine concentration analysis—

Secondary

MeasureTime frame
Immunocyte Profiling—

Countries

Korea, Republic of

Contacts

Public ContactHa Eun Lee

National Cancer Center

77063@ncc.re.kr+82-31-920-2423

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026